These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18236140)

  • 1. Buprederm, a new transdermal delivery system of buprenorphine: pharmacokinetic, efficacy and skin irritancy studies.
    Park I; Kim D; Song J; In CH; Jeong SW; Lee SH; Min B; Lee D; Kim SO
    Pharm Res; 2008 May; 25(5):1052-62. PubMed ID: 18236140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of transdermal buprenorphine patch in the elderly.
    Al-Tawil N; Odar-Cederlöf I; Berggren AC; Johnson HE; Persson J
    Eur J Clin Pharmacol; 2013 Feb; 69(2):143-9. PubMed ID: 22706617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects.
    Wang Y; Cipriano A; Munera C; Harris SC
    J Clin Pharmacol; 2016 Oct; 56(10):1263-71. PubMed ID: 26865472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels.
    Kapil RP; Cipriano A; Friedman K; Michels G; Shet MS; Colucci SV; Apseloff G; Kitzmiller J; Harris SC
    J Pain Symptom Manage; 2013 Jul; 46(1):65-75. PubMed ID: 23026548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Analgesic Patches in Cynomolgus Macaques (
    Smith AA; Halliday LC; Lindeblad MO; Fortman JD
    J Am Assoc Lab Anim Sci; 2019 May; 58(3):356-361. PubMed ID: 31010456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine and the transdermal system: the ideal match in pain management.
    Budd K
    Int J Clin Pract Suppl; 2003 Feb; (133):9-14; discussion 23-4. PubMed ID: 12665118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial.
    Sittl R; Griessinger N; Likar R
    Clin Ther; 2003 Jan; 25(1):150-68. PubMed ID: 12637117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.
    Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J
    Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma buprenorphine concentrations after the application of a 70 microg/h transdermal patch in dogs. Preliminary report.
    Andaluz A; Moll X; Ventura R; Abellán R; Fresno L; García F
    J Vet Pharmacol Ther; 2009 Oct; 32(5):503-5. PubMed ID: 19754919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits.
    Askar R; Fredriksson E; Manell E; Hedeland M; Bondesson U; Bate S; Olsén L; Hedenqvist P
    BMC Vet Res; 2020 Nov; 16(1):436. PubMed ID: 33176781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study.
    Karlsson M; Berggren AC
    Clin Ther; 2009 Mar; 31(3):503-13. PubMed ID: 19393841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pain therapy in the elderly:7-day transdermal buprenorphine patch in clinical practice. Results of a non-interventional study].
    Wahle K; Krings D; Schwenke K
    MMW Fortschr Med; 2013 Mar; 155 Suppl 1():25-31. PubMed ID: 23678668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers.
    Schmid-Grendelmeier P; Pokorny R; Gasser UE; Richarz U
    Curr Med Res Opin; 2006 Mar; 22(3):501-9. PubMed ID: 16574034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine TTS for children--a review of the drug's clinical pharmacology.
    Michel E; Anderson BJ; Zernikow B
    Paediatr Anaesth; 2011 Mar; 21(3):280-90. PubMed ID: 21091589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine.
    Koltzenburg M; Pokorny R; Gasser UE; Richarz U
    Pain; 2006 Dec; 126(1-3):165-74. PubMed ID: 16901645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Converting from Transdermal to Buccal Formulations of Buprenorphine: A Pharmacokinetic Meta-Model Simulation in Healthy Volunteers.
    Priestley T; Chappa AK; Mould DR; Upton RN; Shusterman N; Passik S; Tormo VJ; Camper S
    Pain Med; 2018 Oct; 19(10):1988-1996. PubMed ID: 29036723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a transdermal matrix patch of buprenorphine in cats: preliminary pharmacokinetic and pharmacodynamic data.
    Murrell JC; Robertson SA; Taylor PM; McCown JL; Bloomfield M; Sear JW
    Vet Rec; 2007 Apr; 160(17):578-83. PubMed ID: 17468320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of buprenorphine after intravenous administration in the mouse.
    Yu S; Zhang X; Sun Y; Peng Y; Johnson J; Mandrell T; Shukla AJ; Laizure SC
    J Am Assoc Lab Anim Sci; 2006 May; 45(3):12-6. PubMed ID: 16642964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.